Vitamin D deficiency has been associated with risk of overt cardiovascular disease (CVD), but associations with subclinical disease are not well characterized. Hence, we examined associations of circulating vitamin D concentrations and left ventricular (LV) geometry and function by echocardiography at baseline and after 5 years in a communitybased study.
Introduction
In the ageing population, reduced eating and intestinal absorption of nutrients, including vitamins, and diminished skin synthesis of vitamin D predispose to vitamin D deficiency, which is a wellknown risk factor for diseases involving the musculoskeletal system, such as osteoporosis and osteomalacia. 1, 2 Studies in model animals have indicated that vitamin D affects heart geometry and function. 3 -5 Vitamin D receptors have been detected in cardiac muscle, and the cardiomyocyte-specific depletion of such receptors in knock-out mice is associated with a hypertrophy of cardiac cells. 6 It has also been shown in animal models that vitamin D may repress renin expression and may lower blood pressure. 7 Deficiency of vitamin D could therefore increase blood pressure and promote hypertrophy. Vitamin D deficiency was repeatedly found to be a strong and independent risk factor for incident cardiovascular events in humans. 8 -11 Moreover, studies in subjects with prevalent heart † These two authors contributed equally to this work.
failure have been supportive of an association between vitamin D levels and heart function and geometry, where vitamin D-deficient subjects had worse left ventricular (LV) function and larger endsystolic diameters. 12 -14 Further, survival time and rehospitalization after heart failure were negatively affected by vitamin D levels. 15 -17 The association between vitamin D and heart function and geometry shown in humans may, however, be an effect by reverse causation, where people with prevalent heart failure are less likely to be exposed to sunlight, and as a consequence to have lower vitamin D levels. There is a need for prospective studies of the role of vitamin D in subjects without prior heart failure. Based on the above observations, we hypothesized that there is also a link between circulating vitamin D concentrations and LV geometry and function in individuals without heart failure. Hence, we examined the associations of serum 25-dihydroxyvitamin-D (25-OH D) and echocardiographic LV measurements at baseline and after 5 years in a community-based sample of elderly men and women without known prior myocardial infarctions, heart failure, or prevalent valvular disease.
Methods

Study population
Study participants were randomly sampled from all men and women at age 70 in Uppsala County in 2001 (described in detail at http://www. medsci.uu.se/pivus/pivus.htm). Of the 2025 individuals invited, 1016 participated. All participants underwent a medical examination including a detailed questionnaire on lifestyle and socio-economic factors, 7-day dietary intake records, fasting blood sampling, blood pressure (BP), and anthropometric measurements, as previously described. 18 Blood and plasma samples were frozen immediately after collection and stored at -708C until analyses. The PIVUS study was approved by the Ethics Committee of the Uppsala University (2005-04-06; Dnr: 2005-M-079), and written informed consent was obtained from all participants.
Participants were excluded from the present investigation for the following reasons: prior hospitalization for myocardial infarction (n ¼ 72), prior or prevalent congestive heart failure (n ¼ 22), prevalent significant valvular disease (n ¼ 21), lack of serum 25-OH D results (n ¼ 10), or missing data on confounders (n ¼ 21). After these exclusions, 870 eligible individuals (52% women) were included and constituted the study sample in the present analysis in the cross-sectional design. In the longitudinal analyses, we additionally excluded individuals who did not participate in the follow-up examination (n ¼ 149), and those experiencing a myocardial infarction during the follow-up (n ¼ 24); hence, the final study sample for the longitudinal analysis was 697 individuals. Baseline biochemical and echocardiographic measurements were compared between the final study sample for longitudinal analysis and those not included using the Student's t-test.
Baseline examination
Prior to the physical examination, all participants completed a questionnaire concerning their medical history, regular medication, and smoking habits. 19 They were investigated in the morning and no medication was taken on the morning of the investigation. BP was measured in the supine position in a quiet room at constant temperature. 
Follow-up assessment
Each participant was re-examined 5 years (at age 75) after the initial baseline examination. Echocardiographic measurements were performed at this re-examination using the same methods and by the same echocardiography examiner.
Statistical analysis
We evaluated the distribution of all variables graphically and using Shapiro-Wilk tests. The E/A ratio, fasting glucose, calcium, and parathyroid hormone were non-normally distributed and hence were logarithmically transformed; all other variables were normally distributed. We studied associations of 25-OH D and one echocardiographic variable at a time (as the dependent variable) adjusting for potential confounders in three sets of models: (A) adjusting for age, sex, examination month, and body mass index (BMI); (B) adjusting for age, sex, examination month, BMI, smoking, total cholesterol, HDL cholesterol, systolic BP, creatinine, antihypertensive treatment, diabetes, and a variable for self-reported prior or prevalent angina, prior hospitalization for stroke, or treatment with percutaneous transluminal coronary angioplasty (PTCA) and coronary artery bypass grafting (CABG); and (C) adjusting for age, sex, examination month, BMI, smoking, total cholesterol, HDL cholesterol, systolic BP, creatinine, antihypertensive treatment, diabetes, self-reported prior or prevalent angina, prior hospitalization for stroke, or treatment with PTCA/CABG, calcium, phosphate, magnesium, and parathyroid hormone. 24, 25 In the longitudinal analysis, we additionally adjusted for time between the two examinations (in days) and
echocardiographic measures at baseline in all three models. In secondary analyses, we additionally adjusted for antihypertensive treatment at age 75 (in addition to all covariates in models C); and we also studied the associations of 25-OH D at baseline with echocardiographic measures at age 75, using the same models as for age 70 cross-sectional analysis. In line with the longitudinal secondary analysis, we additionally adjusted for antihypertensive treatment at age 75 (in addition to all covariates in models C). We used linear regression models to assess the relationship of 25-OH D and potential confounders as independent variables, and LV measures as dependent variables in separate models. Linearity was confirmed using spline analyses. In cross-sectional analysis, 25-OH D, confounders, and echocardiographic measures were assessed at baseline, while in longitudinal analysis, 25-OH D and confounders were assessed at baseline, and change in respective echocardiographic variable between age 70 and 75 was used as the outcome variable. We examined effect modification by sex by testing the statistical significance of the two-way interaction term between sex and 25-OH D in models C for each echocardiographic variable as outcome. A two-tailed P-value ,0.05 was considered statistically significant. Analyses were performed using STATA version 11.0 (Stata Corp, College Station, TX, USA).
Results
Baseline characteristics including circulating 25-OH D levels and echocardiographic measures at baseline and follow-up are presented in Table 1 . Generally, 10% were current smokers and 10% had diabetes. Twenty-eight per cent of the eligible cohort received antihypertensive treatment. The overall mean 25-OH D levels were 57.6 + 19.5 nmol/L, and the levels were higher in males (60.5 + 19.9 nmol/L) than in females (55.0 + 18.7 nmol/L) (P,0.001). At baseline, 19 (2.1%) of the participants were considered as severely vitamin D deficient. Over the 5 years of follow-up, the measures of cardiac geometry (LV mass, LV mass index, and LV end-systolic, LV end-diastolic, and left atrial diameter) tended to increase, whereas measures of LV systolic and diastolic function (fractional shortening, intraventricular relaxation time, and E/A ratio) tended to decrease.
In regression models adjusted only for age, sex, examination month, and BMI (model A), higher 25-OH D was negatively associated with LV end-systolic diameter, but positively associated with fractional shortening and ejection fraction ( Table 2 , second column). When additionally adjusting for cardiovascular (CV) risk factors (model B), these associations were similar ( Table 2 , third column). Taking also biomarkers from the calcium/vitamin D pathway (calcium, phosphate, magnesium, and parathyroid hormone) into account (model C, Table 2 , last column), similar results were observed. Stratifying by groups of vitamin D deficiency (severe deficiency defined as 25-OH D , 25 nmol/L, and vitamin D sufficiency defined as 25-OH D . 75 nmol/L) confirmed these observations (Figure 1) .
In addition to cross-sectional analyses, we performed longitudinal analyses of associations of 25-OH D at baseline and 5-year change of echocardiography LV measures. In these analyses, no significant associations were observed between 25-OH D at baseline and changes in LV measures over time ( that the association of 25-OH D and cardiac geometry and function was not modified by sex.
Discussion
Main findings
In our large, community-based study, we report that higher circulating serum vitamin D levels were significantly associated with decreased LV end-systolic diameter and increased measures of systolic function at baseline in cross-sectional analyses, even after adjusting for traditional CV disease (CVD) risk factors, as well as biomarkers from the calcium/vitamin D pathway (calcium, phosphate, magnesium, and parathyroid hormone). As studies of the role of biomarkers from this pathway for LV geometry and function are conflicting, 26 -30 we compared models with or without adjustment for these variables; the results being very similar. In summary, these cross-sectional analyses indicate an association between higher circulating vitamin D levels and measures of better LV systolic function and smaller LV end-systolic diameter. In contrast, all results from our longitudinal analyses relating circulating 25-OH D to 5-year change in LV function and geometry were non-significant. Moreover, we did not observe any significant association between vitamin D levels at age 70 and echocardiographic measures at age 75. These observations argue against vitamin D levels being causally related to LV systolic function and geometry; however, an alternative explanation of the lack of associations could be regression towards the mean. Another source of bias could be a so-called 'healthy cohort effect' that potentially could explain the null finding of the longitudinal analyses. This is a source of selection bias that can arise when only a subset of the original cohort comes back for the re-examination; hence, we compared individuals that attended the re-examination with those that did not. Non-participants in longitudinal analysis indeed had significantly lower vitamin D, higher LV mass, and larger LV end-diastolic diameter than participants in longitudinal analysis (P,0.05). We consider this as supportive of the presence of some degree of 'healthy cohort bias'.
Previous studies
Our findings are consistent with those cross-sectional studies in German and American heart failure patients showing vitamin D deficiency associated with worse LV function. 12, 13 Moreover, male
Italian male heart failure patients with 25-OH D ,25 nmol/L demonstrated significantly higher end-systolic diameters and reduced fractional shortening, compared with heart failure patients with 25-OH D ≥25 nmol/L, an observation that is also consistent with our cross-sectional analyses. 14 Further, in a German study of patients with coronary calcifications, lower vitamin D levels were found to be associated with higher LV relative wall thickness; 31 and the findings were also supported by another study of patients on haemodialysis. 32 Decreased LV end-diastolic and end-systolic volumes and improved fractional shortening were also noted after a micronutrient supplementation including vitamin D in elderly patients with chronic heart failure. 33 Moreover, three studies recently showed an association of low vitamin D levels with shorter survival and increased rehospitalization rates in heart failure patients. 15 -17 Studies in opposition to our results include a study of 648 elderly individuals from the population-based Hoorn cohort, where serum levels of 25-OH D were reported as not being significantly associated with measures of LV geometry or function. 34 An 8-year follow-up was recently published on 256 of the subjects, and the results were still mainly negative for heart structure and function. 35 Another study not supporting a causal relationship of vitamin D to heart function and geometry is the study by Thadhani et al., who performed a double-blinded placebocontrolled 48 week therapy clinical trial with paricalcitol in 227 patients with chronic kidney disease. The therapy did not alter LV mass index or improve measures of diastolic dysfunction. 36 
Possible mechanisms
Vitamin D has been hypothesized to play an important role in reduction of LV hypertrophy and function partly through modulation of the renin -angiotensin system (RAS), which plays a key role in the regulation of volume and blood pressure homeostasis. 37, 38 Vitamin D functions as an endocrine suppressor of renin biosynthesis, and the subsequent genetic disruption of the vitamin D receptor (VDR) could result in overstimulation of the RAS, leading to high blood pressure and cardiac hypertrophy. 7, 38, 39 Also, vitamin D deficiency has been observed to induce myocardial hypertrophy and extracellular matrix production and deposition in myocardial tissue of rats. 40 -43 Mediated by matrix metalloproteinase, extracellular matrix remodelling may be involved in progressive LV remodelling, dilatation, and heart failure. 39 In a healthy Indo-Asian population, plasma metalloproteinase levels were inversely related to vitamin D status. 44 Furthermore, after 1 year treatment with vitamin D, mean plasma metalloproteinase levels were decreased significantly. At the molecular level, vitamin D also has intriguing immunoregulatory and DNA-protective properties.
-48
Strengths and limitations
Our study has several strengths. First, we included individuals from the general population, rather than patients, and had a larger sample size compared with previous studies. Secondly, we included both cross-sectional (baseline) and longitudinal (tracking of 5 years) analyses with repeated LV measurements in a community setting. Thirdly, we excluded individuals with known CVD at baseline (in cross-sectional and longitudinal analyses) and interim myocardial infarction (only in longitudinal analyses) to rule out the reverse causality. However, there are also some limitations of our study. Since we only measured vitamin D concentrations at the age of 70, but not at 75, it is not possible to study how changes of vitamin D levels track with changes in echocardiography LV measures over time. Moreover, we only included individuals residing in Uppsala, Sweden at the age of 70 (resulting in an ethnically homogenous group), and therefore, our findings may not be generalizable to other age and ethnic groups. Although we additionally adjusted calcium, phosphate, magnesium, and parathyroid hormone levels, it is still difficult to evaluate the relative importance and relationship between all these competing factors which may influence the cardiac abnormalities. 49 Given that validating studies in independent cohorts are essential for demonstrating the importance of these clinical findings, future research in healthy subjects across ages and regions are still warranted. Finally, even though our study included a longitudinal component, an observational study like this can never firmly establish or refute causality.
Conclusions
In our community-based study among the elderly, we found higher circulating vitamin D concentrations to be associated with better LV systolic function and smaller LV end-systolic diameter at baseline. This association persisted after adjusting for several potential confounders. The role of vitamin D in LV pathophysiology could be established ultimately only through a well-designed randomized clinical trial.
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